11 research outputs found
Upscaling in vertically fractured oil reservoirs using homogenization
Flow modeling in fractured reservoirs is largely confined to the so-called sugar cube model. Here, however, we consider vertically fractured reservoirs, i.e., the situation that the reservoir geometry can be approximated by fractures enclosed columns running from the base rock to the cap rock (aggregated columns). This article deals with the application of the homogenization method to derive an upscaled equation for fractured reservoirs with aggregated columns. It turns out that vertical flow in the columns plays an important role, whereas it can be usually disregarded in the sugar cube model. The vertical flow is caused by coupling of the matrix and fracture pressure along the vertical faces of the columns. We formulate a fully implicit three-dimensional upscaled numerical model. Furthermore, we develop a computationally efficient numerical approach. As found previously for the sugar cube model, the Peclet number, i.e., the ratio between the capillary diffusion time in the matrix and the residence time of the fluids in the fracture, plays an important role. The gravity number plays a secondary role. For low Peclet numbers, the results are sensitive to gravity, but relatively insensitive to the water injection rate, lateral matrix column size, and reservoir geometry, i.e., sugar cube versus aggregated column. At a low Peclet number and sufficiently low gravity number, the effective permeability model gives good results, which agree with the solution of the aggregated column model. However, ECLIPSE simulations (Barenblatt orWarren and Root (BWR) approach) show deviations at low Peclet numbers, but show good agreement at intermediate Peclet numbers. At high Peclet numbers, the results are relatively insensitive to gravity, but sensitive to the other conditions mentioned above. The ECLIPSE simulations and the effective permeability model show large deviations from the aggregated column model at high Peclet numbers.We conclude that at low Peclet numbers, it is advantageous to increase the water injection rate to improve the net present value. However, at high Peclet numbers, increasing the flow rate may lead to uneconomical water cuts.GeotechnologyCivil Engineering and Geoscience
Introduzindo wwhypda: uma base de dados colaborativa mundial de parâmetros hidrogeológicos
Fracture aquifers identification in the Zou basin (West Africa) using remote sensing and GIS
Recommended from our members
Preclinical Evaluation of Efficacy and Safety of an Improved Lentiviral Vector for the Treatment of β-Thalassemia and Sickle Cell Disease
A previously published clinical trial demonstrated the benefit of autologous CD34+ cells transduced with a self-inactivating lentiviral vector (HPV569) containing an engineered β-globin gene (βA-T87Q globin) in a subject with β-thalassemia major. This vector has been modified to increase transduction efficacy without compromising safety. In vitro analyses indicated that the changes resulted in both increased vector titers (3 to 4 fold) and increased transduction efficacy (2 to 3 fold). An in vivo study in which 58 β-thalassemic mice were transplanted with vector- or mock-transduced syngenic bone marrow cells indicated sustained therapeutic efficacy. Secondary transplantations involving 108 recipients were performed to evaluate long-term safety. The six month study showed no hematological or biochemical toxicity. Integration site (IS) profile revealed an oligo/polyclonal hematopoietic reconstitution in the primary transplants and reduced clonality in secondary transplants. Tumor cells were detected in the secondary transplant mice in all treatment groups (including the control group), without statistical differences in the tumor incidence. Immunohistochemistry and quantitative PCR demonstrated that tumor cells were not derived from transduced donor cells. This comprehensive efficacy and safety data provided the basis for initiating two clinical trials with this second generation vector (BB305) in Europe and in the USA in patients with β-thalassemia major and sickle cell disease